3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
12
Venous Thrombosis
9
Pulmonary Embolism
9
Neoplasms
8
Thrombosis
4
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lung Neoplasms
3
Thromboembolism
2
Neoplasm Metastasis
2
Lymphoma
2
Hemorrhage
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombophilia
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Interventions
Sorafenib
131
lenvatinib
115
Bevacizumab
88
Radiosurgery
69
atezolizumab
55
sintilimab
54
Nivolumab
51
durvalumab
43
Hepatectomy
43
Fluorouracil
42
apatinib
41
Oxaliplatin
41
camrelizumab
38
Radiofrequency Ablation
38
pembrolizumab
36
Radiotherapy
36
tislelizumab
35
Leucovorin
31
Magnetic Resonance Spectroscopy
30
Immune Checkpoint Inhibitors
28
Doxorubicin
28
Folfox protocol
26
tremelimumab
25
regorafenib
25
Cisplatin
20
spartalizumab
19
donafenib
19
Gemcitabine
19
Cyclophosphamide
19
toripalimab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Hepatocellular
×
Dalteparin
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled